 | Up a level |
Journal Article
Andersson, E. I., Puetzer, S., Yadav, B., Dufva, O., Khan, S., He, L., Sellner, L., Schrader, A., Crispatzu, G., Oles, M., Zhang, H., Adnan-Awad, S., Lagstrom, S., Bellanger, D., Mpindi, J. P., Eldfors, S., Pemovska, T., Pietarinen, P., Lauhio, A., Tomska, K., Cuesta-Mateos, C., Faber, E., Koschmieder, S., Bruemmendorf, T. H., Kytola, S., Savolainen, E-R, Siitonen, T., Ellonen, P., Kallioniemi, O., Wennerberg, K., Ding, W., Stern, M-H, Huber, W., Anders, S., Tang, J., Aittokallio, T., Zenz, T., Herling, M. and Mustjoki, S. (2018). Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. Leukemia, 32 (3). S. 774 - 788. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Bos, M., Gardizi, M., Heukamp, L. C., Merkelbach-Bruse, S., Schildhaus, H. -U., Scheffler, M., Nogova, L., Mattonet, C., Serke, M., Randerath, W. J., Gerigk, U., Bruemmendorf, T. H., Krueger, S., Panse, J., Kaminski, B., Reiser, M., Buettner, R. and Wolf, J. (2014). The Network Genomic Medicine: A prospective comprehensive molecular screening network for implementation of personalized lung cancer therapy. Oncol. Res. Treat., 37. S. 91 - 92. BASEL: KARGER. ISSN 2296-5262
Bos, M., Gardizi, M., Heukamp, L. C., Schildhaus, H. -U., Merkelbach-Bruse, S., Nogova, L., Scheffler, M., Serke, M., Schulz, H., Krueger, S., Bruemmendorf, T. H., Panse, J., Schmitz, S., Gerigk, U., Randerath, W. J., Ko, Y. D., Kambartel, K., Huenerlituerkoglu, A. -N., Buettner, R. and Wolf, J. (2014). A retrospective analysis of overall survival of ALK translocation - and of EGFR mutation positive NSCLC patients treated with and without personalized therapy. Oncol. Res. Treat., 37. S. 91 - 92. BASEL: KARGER. ISSN 2296-5262
Braig, M., Paellmann, N., Preukschas, M., Steinemann, D., Hofmann, W., Gompf, A., Streichert, T., Braunschweig, T., Copland, M., Rudolph, K. L., Bokemeyer, C., Koschmieder, S., Schuppert, A., Balabanov, S. and Bruemmendorf, T. H. (2014). A 'telomere-associated secretory phenotype' cooperates with BCR-ABL to drive malignant proliferation of leukemic cells. Leukemia, 28 (10). S. 2028 - 2040. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Hehlmann, R., Lauseker, M., Saussele, S., Pfirrmann, M., Krause, S., Kolb, H. J., Neubauer, A., Hossfeld, D. K., Nerl, C., Gratwohl, A., Baerlocher, G. M., Heim, D., Bruemmendorf, T. H., Fabarius, A., Haferlach, C., Schlegelberger, B., Mueller, M. C., Jeromin, S., Proetel, U., Kohlbrenner, K., Voskanyan, A., Rinaldetti, S., Seifarth, W., Spiess, B., Balleisen, L., Goebeler, M. C., Haenel, M., Ho, A., Dengler, J., Falge, C., Kanz, L., Kremers, S., Burchert, A., Kneba, M., Stegelmann, F., Koehne, C. A., Lindemann, H. W., Waller, C. F., Pfreundschuh, M., Spiekermann, K., Berdel, W. E., Mueller, L., Edinger, M., Mayer, J., Beelen, D. W., Bentz, M., Link, H., Hertenstein, B., Fuchs, R., Wernli, M., Schlegel, F., Schlag, R., de Wit, M., Truemper, L., Hebart, H., Hahn, M., Thomalla, J., Scheid, C., Schafhausen, P., Verbeek, W., Eckart, M. J., Gassmann, W., Pezzutto, A., Schenk, M., Brossart, P., Geer, T., Bildat, S., Schaefer, E., Hochhaus, A. and Hasford, J. (2017). Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia, 31 (11). S. 2398 - 2407. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Koleczko, S., Schapers, C., Scheffler, M., Ihle, M., Kostenko, A., Michels, S., Fischer, R., Nogova, L., Serke, M., Kaminsky, B., Benedikter, J., Bruemmendorf, T. H., Ficker, J. H., Lorenz, J., Schulte, C., Schulze-Olden, S., Brandes, V, Abdulla, D., Ueckeroth, F., Thurat, M., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2016). A comprehensive analysis of potentially targetable genetic aberrations and clinical findings in 821 patients with squamous-cell NSCLC - a comparison of NGM and TCGA LUSC data. Oncol. Res. Treat., 39. S. 32 - 33. BASEL: KARGER. ISSN 2296-5262
Schrader, A., Crispatzu, G., Oberbeck, S., Mayer, P., Putzer, S., von Jan, J., Vasyutina, E., Warner, K., Weit, N., Pflug, N., Braun, T., Andersson, E. I., Yadav, B., Riabinska, A., Maurer, B., Ferreira, M. S. Ventura, Beier, F., Altmueller, J., Lanasa, M., Herling, C. D., Haferlach, T., Stilgenbauer, S., Hopfinger, G., Peifer, M., Bruemmendorf, T. H., Nuernberg, P., Elenitoba-Johnson, K. S. J., Zha, S., Hallek, M., Moriggl, R., Reinhardt, H. C., Stern, M. -H., Mustjoki, S., Newrzela, S., Frommolt, P. and Herling, M. (2018). Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. Nat. Commun., 9. LONDON: NATURE PUBLISHING GROUP. ISSN 2041-1723
Tschanter, P., Krug, U., Fueller, M., Klein, M., Goellner, S., Rohde, C., Roellig, C., Thiede, C., Lilly, M. A., Haack, B., Koschmieder, A., Stelljes, M., Dugas, M., Koschmieder, S., Gerss, J., Butterfass-Bahloul, T., Wagner, R., Eveslage, M., Thiem, U., Krause, S. W., Kaiser, U., Kunzmann, V, Steffen, B., Noppeney, R., Herr, W., Baldus, C. D., Schmitz, N., Goetze, K., Reichle, A., Kaufmann, M., Neubauer, A., Schaefer-Eckart, K., Haenel, M., Peceny, R., Frickhofen, N., Kiehl, M., Giagounidis, A., Goerner, M., Repp, R., Link, H., Kiani, A., Naumann, R., Bruemmendorf, T. H., Serve, H., Ehninger, G., Berdel, W. E. and Mueller-Tidow, C. (2015). DNMT3A mutations in exon 23 are associated with improved survival in AML patients treated with Azacytidine plus standard chemotherapy. Oncol. Res. Treat., 38. S. 122 - 123. BASEL: KARGER. ISSN 2296-5262